72482-64-5

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Difluorobenzoyl chloride is used as a pharmaceutical intermediate for the synthesis of various drugs and medicinal compounds. Its unique chemical structure allows it to be a valuable building block in the development of new pharmaceuticals.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2,4-Difluorobenzoyl chloride is utilized in the synthesis of specific compounds, such as 3-oxocyclohex-1-enyl 2,4-difluorobenzoate. This application showcases its versatility and importance in creating a wide range of chemical products.
Overall, 2,4-Difluorobenzoyl chloride is a versatile and valuable compound in both the pharmaceutical and chemical synthesis industries, playing a crucial role in the development and production of various drugs and chemical products.

InChI:InChI=1S/C7H3ClF2O/c8-7(11)5-2-1-4(9)3-6(5)10/h1-3H

Upstream product

• 1583-58-0 2,4-difluoro-benzoic acid 
• 79-37-8 oxalyl dichloride 
• 67640-39-5 2,4-difluorobenzoyl fluoride 
• 13656-36-5 3,5-dichloro-2,4,6-trifluorobenzoic acid 
• 729559-69-7 N-(4-cyanophenyl)-2,4-difluorobenzamide 

Downstream Products

• 136741-46-3 (5-Chloro-2-hydroxy-4-methoxy-phenyl)-(2,4-difluoro-phenyl)-methanone 
• 109790-33-2 2,4-Difluoro-N-(2-hydroxy-phenyl)-benzamide 
• 119983-22-1 2-amino-5-ethyl-2',4'-difluorobenzophenone 
• 1045725-79-8 (S)-1-(2,4-Difluoro-benzoyl)-pyrrolidine-2-carboxylic acid 
• 201686-67-1 6-[bis-(2,4-difluoro-benzoyl)-amino]-nicotinic acid ethyl ester 
• 325808-27-3 1-(2,4-difluorobenzoyl)-4-(3-hydroxyphenyl)piperidine 
• 389600-22-0 N-[2-[(3-(allyloxycarbonyl)phenyl)methoxy]-1(S)-cyanoethyl]-Nα-(2,4-difluorobenzoyl)-3-methyl-L-phenylalaninamide 

Relevant academic research and scientific papers

Experimental and theoretical structure characterization of two isoniazid derivatives: 2,4-Difluoro-N′-isonicotinoylbenzohydrazide and 2,4-dichloro-N′-isonicotinoylbenzohydrazide hydrochloride

An X-ray and a theoretical study of the structure of the isoniazid derivatives, 2,4-difluoro-N′-isonicotinoylbenzohydrazide, 3, and 2,4-dichloro-N′-isonicotinoylbenzohydrazide hydrochloride, [4H+, Cl-, 2(H2O)], are reported. Quantum chemical calculations as well as conformational analysis are presented with the isolated cations [3H+] and [4H+], where the former was protonated in silico to allow direct comparison of results. Supermolecule calculations were also carried out with the asymmetric unit of [4H+, Cl-, 2(H2O)], which is comprised of two independent cations (4H+), two chloride ions and four water molecules. Our results indicate that the crystal structures, although clearly representing accessible conformations, are highly distorted in comparison to the predicted lower energy conformers in the gas-phase. These distortions are most probably imposed by polar and electrostatic interactions within the crystal packing. In general, the calculated potential energy surfaces (PES) for both isoniazid derivatives are fairly flat, a feature confirmed by the low energetic difference calculated for several conformers corresponding to local minima in PES. Noteworthy, the fluorinated compound [3H+] shows an important additional energy barrier for rotation around the bond connecting the halogenated ring to the proximate carbonyl due to a strong internal hydrogen bond involving the fluorine atom.

Remarkably Efficient Iridium Catalysts for Directed C(sp2)-H and C(sp3)-H Borylation of Diverse Classes of Substrates

Here we describe the discovery of a new class of C-H borylation catalysts and their use for regioselective C-H borylation of aromatic, heteroaromatic, and aliphatic systems. The new catalysts have Ir-C(thienyl) or Ir-C(furyl) anionic ligands instead of the diamine-type neutral chelating ligands used in the standard C-H borylation conditions. It is reported that the employment of these newly discovered catalysts show excellent reactivity and ortho-selectivity for diverse classes of aromatic substrates with high isolated yields. Moreover, the catalysts proved to be efficient for a wide number of aliphatic substrates for selective C(sp3)-H bond borylations. Heterocyclic molecules are selectively borylated using the inherently elevated reactivity of the C-H bonds. A number of late-stage C-H functionalization have been described using the same catalysts. Furthermore, we show that one of the catalysts could be used even in open air for the C(sp2)-H and C(sp3)-H borylations enabling the method more general. Preliminary mechanistic studies suggest that the active catalytic intermediate is the Ir(bis)boryl complex, and the attached ligand acts as bidentate ligand. Collectively, this study underlines the discovery of new class of C-H borylation catalysts that should find wide application in the context of C-H functionalization chemistry.

Br?nsted acid-catalyzed chlorination of aromatic carboxylic acids

The chlorination of aromatic carboxylic acids with SOCl2 has been effectively performed by reacting with a Br?nsted acid as the catalyst. Based on this discovery, an efficient catalytic method that is cheaper than traditional catalytic methods was developed. 20 substrates were chlorinated offering excellent yields in a short reaction time. And the SOCl2/Br?nsted acid system has been used in a larger scale preparative reaction. A dual activation mechanism was proposed to prove the irreplaceable system of SOCl2/Br?nsted acid.

Micellar Catalysis for Sustainable Hydroformylation

It is here reported a fully sustainable and generally applicable protocol for the regioselective hydroformylation of terminal alkenes, using cheap commercially available catalysts and ligands, in mild reaction conditions (70 °C, 9 bar, 40 min). The process can take advantages from both micellar catalysis and microwave irradiation to obtain the linear aldehydes as the major or sole regioisomers in good to high yields. The substrate scope is largely explored as well as the application of hydroformylation in tandem with intramolecular hemiacetalization thus demonstrating the compatibility with a broad variety of functional groups. The reaction is efficient even in large scale and the catalyst and micellar water phase can be reused at least 5 times without any impact in reaction yields. The efficiency and sustainability of this protocol is strictly related to the in situ transformation of the aldehyde into the corresponding Bertagnini's salt that precipitates in the reaction mixture avoiding organic solvent mediated purification steps to obtain the final aldehydes as pure compounds.

PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) and (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating H1 and 5-HT2A receptors and are to be used in the treatment of sleep disorders, such as sleep fragmentation, disturbed sleep/arousals, and arousal threshold.

Benzoyl-containing rupestonic acid methyl ester derivative as well as preparation method and application thereof

The invention relates to a benzoyl-containing rupestonic acid methyl ester derivative as well as a preparation method and application thereof. Rupestonic acid and dimethyl sulfate react to obtain rupestonic acid methyl ester, 2-hydroxyl rupestonic acid methyl ester is prepared under oxidation of camphor sulfonyl acridine, and then the 2-hydroxyl rupestonic acid methyl ester reacts with different substituted benzoyl chloride under the catalysis of DMAP to obtain the 1d-15d benzoyl-containing rupestonic acid methyl ester derivative. The method has the advantages of mild reaction conditions and simple experimental steps. The obtained benzoyl-containing rupestonic acid methyl ester derivative 1d-15d is subjected to an anti-H3N2 influenza A virus activity test in 1d-15d. Experimental results show that the compounds 1d, 2d, 4d, 5d, 7d, 8d, 12d, 13d and 15d can be applied to preparation of drugs for resisting influenza A H3N2 virus.

Preparation method and application of tetrahydrobenzothiophene compound and pharmaceutical composition

The invention belongs to the field of medicines, and particularly relates to a tetrahydrobenzothiophene compound as well as a pharmaceutical composition and a preparation method and application thereof. The tetrahydrobenzothiophene compound is a compound I as shown I. In-flight R1 And R2 The C1 -4 is a saturated/unsaturated hydrocarbon group. - OCH3 , OCH2 CH3 Phenyl, substituted phenyl, NO2 One - COR of - OH - F, Cl - Br. I - H R1 AND R2 Or different. R3 It is-F. - Cl, Br, I, OH, Amino, C1 -4 saturated/unsaturated hydrocarbon group, OCH3 , OCH2 CH3 , H, Wherein one of them is, n ≥ 5, n Being an integer. The compound effectively inhibits salmonella by inhibiting the synthesis of ATP-dependent transporter in the lipopolysaccharide synthesis pathway. Aeruginosa, escherichia coli and staphylococcus aureus.

Novel panaxadiol triazole derivatives induce apoptosis in HepG-2 cells through the mitochondrial pathway

In this study, we introduced 1, 2, 4-triazole groups into panaxadiol (PD) to obtain 18 panaxadiol triazole derivatives. Five cancer cells and one normal cell were evaluated for cytotoxicity by MTT assay. The results showed that most of the derivatives could inhibit cancer cell proliferation, and the anti-proliferative activity of compound A1 was the most significant. For HepG-2 cells, the IC50 value was 4.21 ± 0.54 μM, which was nearly 15 times higher than the activity of PD. Further studies showed that compound A1 could induce apoptosis in HepG-2 cells, and could enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Moreover, Western blot analysis showed that after treating HepG-2 cells with compound A1, the expression of p53 protein was increased and the ratio of Bax/Bcl-2 was gradually increased. The cytoplasmic Bax is then translocated to the mitochondria, causing the release of Cyt c protein. Therefore, the results indicate that compound A1 induces apoptosis through the mitochondrial pathway and can be used the potential to develop new anti-proliferative agents.

Heterocyclic compound and preparation and application thereof

The invention relates to bromodomain inhibitors, and provides a compound represented by a general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method thereof, a pharmaceutical composition containing the same, and applicationthereof in pharmacy.

Dammarane sapogenin derivative and preparation method and application thereof

The invention belongs to the technical field of medicines, and relates to a dammarane sapogenin derivative and a preparation method and application thereof. A series of dammarane sapogenin derivativesare obtained by combining dammarane sapogenins from plants with different groups. Anticancer activity evaluation and anticancer activity mechanism research are carried out on the derivative, and results show that the prepared dammarane sapogenin derivative has a remarkable anticancer effect, has no toxic effect on normal cells and can be used for preparing drugs for treating cancers.